Search Results for keywords:"federally-funded research"

The National Institutes of Health (NIH) has announced the availability of a government-owned invention for licensing, aimed at speeding up the commercialization of research funded by the government to benefit public health. This invention involves analogues of N-Lactoyl-Phenylalanine (Lac-Phe), which could serve as appetite suppressants and help treat obesity and related diseases. It is currently in the preclinical development stage and is open for licensing under U.S. patent law. Interested parties can contact Malabika Ghosh at the NIH for licensing details.

The National Institutes of Health, part of the U.S. Department of Health and Human Services, has announced an invention available for licensing. This invention is a high-throughput COVID-19 diagnostic test that uses next-generation sequencing to simultaneously detect the virus and the host's response. It aims to provide accurate and fast testing on a large scale, with potential applications in detecting various infectious organisms. The technology reduces reagent use and can also help predict the severity of the disease based on gene expression.

The Department of Health and Human Services, specifically the National Institutes of Health (NIH), announced that certain government-owned inventions are available for licensing. One such invention involves the use of statins, like atorvastatin, to prevent hearing loss caused by chemotherapy drugs like cisplatin. Hearing loss is a common side effect for many cancer patients undergoing treatment, and statins are being explored to mitigate this issue. The announcement highlights both the potential applications for these statins in preventing hearing loss and the readiness of the technology for commercial development.